Peer Review History
| Original SubmissionJanuary 26, 2022 |
|---|
|
PONE-D-22-02590Facemasks: Perceptions and Use in an ED Population During COVID-19PLOS ONE Dear Dr. Eswaran, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Apr 11 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Francesca Baratta, PharmD, PhD Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. One of the noted authors is a group or consortium “The REVVED-UP”. In addition to naming the author group, please list the individual authors and affiliations within this group in the acknowledgments section of your manuscript. Please also indicate clearly a lead author for this group along with a contact email address. 3. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide. 4. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: I Don't Know Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The study presents an important aspect of mask use in vulnerable populations. There are a few considerations that could make the paper more robust and there are some questions needing clarification. The introduction is quite short. Since the focus of the study was vulnerable populations, it would be helpful to include background on rates of COVID infections in this group of individuals compared to the general population or how the pandemic has impacted vulnerable groups differently and puts them at higher risk for COVID related complications. The objective sentence should be clarified. The way it reads it seems as though it is specifically mask wearing in the ED, and not practices by individuals who were treated in the ED. Since not all sites conducted the survey in the same manner (some while in the ED and some after discharge), this may be an additional limitation to note. Subjects may respond differently in different situations. Not sure about the grouping of responses for mask wearing outside the home. This may be ok but would be helpful to include an additional table that shows frequency and percentage for each response of always, most of the time, sometimes and never. Always (100%) is quite different from most of the time (50-99%?). Were respondents provided the percentages (> or < 50% of the time) to help quantify their responses? The reported mask wearing in the results is confusing. Again, would be helpful to provide numbers for each response and then group after that. Survey item number 12 regarding regular clinic or doctor does not specifically state primary care doctor. Is it assumed that respondents understand this item meant primary care doctor? How would it differentiate if they saw a specialist regularly? The health insurance survey response options are confusing. Did all 15 participating sites outside of the lead site offer MediCal, Kaiser or Healthy San Francisco? Each site probably has a similar version of these programs. Is Kaiser considered private insurance? How this data is reported should be clarified and may require to be grouped differently. Could also consider an overall grouping of insured and not insured and then provide the breakdown of different types. On Table 1, results are presented in different ways but it is unclear which is what. Some are median and IQR, some appear to be frequency and percentage and others a range? Ok to report differently but each needs to be stated what is the measure. Otherwise it is confusing. For the supplemental survey items, would consider only including the items that were relevant to the reported results for this study. For example, this study did not report on influenza or COVID vaccinations yet there are survey items included on this. The Discussion could be more robust. More specifics on how this study compares to similar studies should be included. Should elaborate more on the issues presented, especially as related to vulnerable populations. Discussion should note the implications for clinical practice and areas for future or additional research. The timeframe in which the study occured is stated but should be specifically noted it did not include the Delta or Omicron variant surges. Additional study limitation is subject self reported data. There is always the possibility that respondents may not have answered truthfully but rather based on what they felt the healthcare team wanted to hear. The Conclusion section should be more concise. This is typically a short summary of the overall findings. The second part of the conclusions regarding actionalble items and education belong in the discussion. Conclusion should not note anything new that wasn't already discussed. Regarding the figure of percentage of respondents by hospital, it would also be helpful to include something similar with grouping by geographical region. Overall the study is good and I commend the authors for their work. Improving on the points noted will help it to be more meaningful and contribute to the literature on this topic. Reviewer #2: Thank you very much for allowing me to review the submission titled: Facemasks: Perceptions and Use in an ED Population During COVID-19, submitted by Karen Adams et all. This paper is a secondary analysis of an ED based study across the US focusing on safety net EDs in urban academic institutions. Their data is interesting but biased by where the study was run. While they acknowledge that bias in their conclusion, throughout the result section we are able to see the degree of imbalance in their population studied. Their data shows that English was the primary language for 80%, with 81% having a PCP and only 12% being uninsured. By documenting that the white, non Latinx population buys their masks on line, we are left with the suggestion that these are adults of means, with access to on line ordering, a home/stable place of living for product to be delivered to and a credit card to pay the bill. In essence that does not translate to their results being extendable to match what the title of their study is. In general, their population is able to acquire masks and uses them as needed. Only a very few do not want or use masks, and even fewer document that they don’t want to use them. This does not match the large general population that are anti-mask, that uses social media to downplay the risks of COVID and play up the myth that masks are bad for you. Perhaps we would have been better able to judge mask use if we looked at the general population that attended large (political) gatherings or casinos or even looked in states that never had a mask mandate. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
Facemasks: Perceptions and Use in an ED Population During COVID-19 PONE-D-22-02590R1 Dear Dr. Eswaran, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Francesca Baratta, PharmD, PhD Academic Editor PLOS ONE |
| Formally Accepted |
|
PONE-D-22-02590R1 Facemasks: Perceptions and Use in an ED Population During COVID-19 Dear Dr. Eswaran: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Francesca Baratta Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .